Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amino Acid Supplement for IGF-1 in Adults
NCT05599282Phase 2Completed
- Sponsor
- ZandA Technologies
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by ZandA Technologies. Primary endpoint: Serum IGF-1 concentration at 31 days. Started Oct 2022; status: completed.
Beyond the preview
Go deeper on NCT05599282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599282.